CAS 313489-71-3

Formule : C27H33N5O2

InChI : InChI=1S/C27H33N5O2/c1-30-13-10-23(11-14-30)31-15-17-32(18-16-31)27(34)25(21-5-3-2-4-6-21)29-26(33)22-8-7-20-9-12-28-24(20)19-22/h2-9,12,19,23,25,28H,10-11,13-18H2,1H3,(H,29,33)/t25-/m1/s1

Code InChI : VYNKVNDKAOGAAQ-RUZDIDTESA-N

SMILES : CN1CCC(CC1)N2CCN(CC2)C(=O)[C@@H](C3=CC=CC=C3)NC(=O)C4=CC5=C(C=C4)C=CN5

LY 517717

CAS : 313489-71-3

LY 517717

Formule : C₂₇H₃₃N₅O₂

Degré de pureté : 99.5%

Masse moléculaire : 459.58

Ref: 54-BUP07644

LY 517717

CAS : 313489-71-3

Ref: IN-DA00C98U

LY 517717

Produit contrôlé

CAS : 313489-71-3

Formule : C₂₇H₃₃N₅O₂

Couleur et forme : Neat

Masse moléculaire : 459.583

Ref: TR-L486750

LY 517717

CAS : 313489-71-3

LY 517717 is an orally active inhibitor of coagulation factor Xa with antithrombotic activity for the study of venous thromboembolism (VTE).

Formule : C₂₇H₃₃N₅O₂

Degré de pureté : 99.30% - 99.88%

Couleur et forme : Solid

Masse moléculaire : 459.58

Ref: TM-T27920

LY 517717

CAS : 313489-71-3

LY 517717 is an oral, investigational anticoagulant that is being studied as a potential treatment for acute coronary syndrome (ACS). It acts by inhibiting the prothrombinase complex and the activated partial thromboplastin time (APTT). LY 517717 has been shown to be safe and well tolerated in clinical trials. It has also been shown to have a favorable safety profile with no major adverse events or bleeding complications. LY 517717 is currently in clinical development as a potential anticoagulant therapy for ACS.

Formule : C₂₇H₃₃N₅O₂

Degré de pureté : Min. 95%

Masse moléculaire : 459.6 g/mol

Ref: 3D-NMA48971